Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439435 | 0.88 | ENPP3 (0.50) | ENPP1ENPP3TNFCA12CA1 | |
| SCHEMBL28106850 | 0.85 | TOP1 (0.39) | ENPP1ENPP3TNFCA12CA1 | |
| SCHEMBL13458738 | 0.85 | MEN1 (0.47) | ENPP1ENPP3TNFCA12CA1 | |
| SCHEMBL13015739 | 0.85 | CYP1A1 (0.38) | TNFKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3697659 | 0.85 | MEN1 (0.49) | ENPP1ENPP3TNFCA12CA1 | |
| SCHEMBL18092544 | 0.83 | PPARA (0.39) | ENPP1ENPP3KDM4EALDH1A1MAPK1 | |
| SCHEMBL14581515 | 0.83 | TOP1 (0.40) | ENPP1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL16105349 | 0.83 | TNF (0.52) | ENPP1ENPP3TNFCA12CA1 | |
| SCHEMBL29995332 | 0.83 | TNF (0.52) | ENPP1ENPP3TNFCA12CA1 | |
| SCHEMBL22139681 | 0.82 | TOP1 (0.45) | ENPP1ENPP3TNFKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436341-B2 | Electronic device including phenanthroline derivative | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436341-B2 | Electronic device including phenanthroline derivative | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8309731-B2 | Electronic device including phenanthroline derivative | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309731-B2 | Electronic device including phenanthroline derivative | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120065402-A1 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065402-A1 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100207108-A1 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100207108-A1 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010075379-A2 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065402-A1 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | PAH, AHR, TYR | ENPP1 2663/4885ENPP3 1498/4885TNF 4390/4885 |
| US-20100207108-A1 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE | PAH, AHR, TYR | ENPP1 2696/4885ENPP3 1335/4885TNF 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.